Double-Blind Multicentre Comparative Study of Ebastine, Terfenadine and Placebo in the Treatment of Chronic Idiopathic Urticaria in Adults

Summary

Ebastine is a new second generation histamine H₁ receptor antagonist that has shown clinical efficacy in the treatment of seasonal and perennial allergic rhinitis and chronic urticaria after once-daily administration. This double-blind multi-centre randomised placebo-controlled study has investigated the long term efficacy of ebastine 10mg once daily in the treatment of chronic urticaria compared with that of terfenadine 60mg twice daily.

At the end of a 3-month treatment period, ebastine was significantly superior to placebo in improving symptoms of chronic urticaria (including severity of itching, number of wheals per day), and its efficacy was similar to that of terfenadine. In a global assessment of efficacy, investigators considered chronic urticaria to have improved in 73% of ebastine recipients compared with 68% and 52% of patients treated with terfenadine or placebo, respectively. The patients’ assessments of efficacy were similar to those of the investigators.

Ebastine was well tolerated, the incidence and nature of adverse events with this agent being similar to those reported in patients treated with terfenadine or placebo. The most common adverse events were headache and dry mouth.

Thus, these results, which show ebastine to be an effective and well tolerated agent, indicate that the drug should be considered for the first-line therapy of chronic urticaria.